{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers type I interferon signaling and broadens antigen presentation.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination combined with ICI improves tumor control and survival compared to ICI alone.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C03",
      "claim": "The sensitization effect depends on type I interferon signaling and mRNA presence.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C04",
      "claim": "Intratumoral mRNA vaccination creates a more targetable checkpoint axis and increases immune infiltration.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation."
    }
  ]
}
